77422-24-3

Usage

Uses

Used in Pharmaceutical Industry:
4-(4-Chlorobenzenesulfonyl)benzaldehyde is used as an intermediate in the synthesis of anti-inflammatory and anti-cancer drugs. Its unique chemical structure allows it to be a key component in the development of these medications, potentially contributing to their therapeutic effects.
Used in Dye and Pigment Production:
In the chemical industry, 4-(4-Chlorobenzenesulfonyl)benzaldehyde is used in the production of dyes and pigments. Its chemical properties make it suitable for creating a range of colors and hues, which can be applied in various products and applications.
Safety Precautions:
It is important to handle 4-(4-Chlorobenzenesulfonyl)benzaldehyde with caution, as it may pose health risks if not used properly. It should be stored and handled in accordance with safety guidelines to minimize any potential hazards.

Upstream product

• 98-60-2 4-chlorobenzenesulfonyl chloride 
• 14752-66-0 sodium p-chlorobenzenesulphinate 
• 555-16-8 4-nitrobenzaldehdye 
• 137736-07-3 4-(4-chloro-phenylsulfanyl)-benzaldehyde 

Relevant academic research and scientific papers

Oxidation of Aryl Sulfides to Sulfones with Alumina-Supported Ruthenium Catalyst in Dimethyl Carbonate-Water Media

A new procedure for the oxidation of sulfides to sulfones utilizing heterogeneous ruthenium reagent has been developed. A small amount of ruthenium trichloride (RuCl3) supported on alumina and excess sodium metaperiodate (NaIO4) was used to produce the ruthenium oxidizing catalyst in the reaction mixture. Sodium metaperiodate oxidized the pre-catalyst RuCl3 to RuO4 and also maintained a constant supply of RuO4 by oxidizing lower valent ruthenium ions during the course of the reaction. An environmentally friendly solvent mixture of dimethyl carbonate (DMC) and water was employed. A wide variety of aromatic sulfides were oxidized to sulfones in good to excellent yields by utilizing this procedure.

Metal and solvent free selective oxidation of sulfides to sulfone using bifunctional ionic liquid [pmim]IO4

The oxidation of organo-sulfides to sulfones has been accomplished using an easily accessible bifunctional ionic liquid, [pmim]IO4 in the absence of any other oxidants, metal and organic solvent at ambient temperature. A variety of sulfides including dialkyl, aryl-alkyl, diaryl, and aryl-hetero aryl have been oxidized to the corresponding functionalized sulfones in high yields by this procedure.

First palladium-catalyzed denitrated coupling of nitroarenes with sulfinates

The first example of palladium-catalyzed protocol for the denitrated coupling of nitroarenes with sulfinates was developed, achieving aryl and heterocyclic sulfones in moderate to excellent yields. The cyclopalladated ferrocenylimine (I) exhibited highly catalytic activity for this transformation with low catalyst loading (0.75 mol %). The efficiency of this reaction was demonstrated by compatibility with a wide range of groups. Thus, the method represents a simple and facile procedure to access aryl and heterocyclic sulfones.

Arylthiobenzylpiperidine derivatives

This invention is directed to Arylthiobenzylpiperidine derivatives which are ligands at the MCH1 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from obesity which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention.

Arylthiobenzylpiperidine derivatives

This invention is directed to Arylthiobenzylpiperidine derivatives which are ligands at the MCH1 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from obesity which comprises administering to the subject an amount of a compound of the subject invention.